Scarica l'app Stockscreener
105.00
2.82%
-2.995
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Abbott Laboratories Borsa (ABT) Ultime notizie
Abbott Rides Key Diabetes, Oncology and Heart Care Innovation Trends - TradingView
Implicity’s Next-Generation ILR ECG Analyzer Earns FDA Clearance - GlobeNewswire Inc.
FRAUD AND MANIPULATION—N.D. Ill.: Abbott did not commit securities fraud over tainted baby formula - VitalLaw.com
Abbott (ABT) Lands Exclusive Rights To FDA Approved Blood Based CRC Test - Yahoo Finance
Freenome went public for $300 million, then scored a huge victory with colorectal cancer test - The Business Journals
Abbott (ABT) Raised Its Profit Forecast. What’s Driving Its Growth? - Yahoo Finance
Federal Judge Dismisses Abbott Shareholder Lawsuit Over 2022 Infant Formula Recall - Law Commentary
Abbott Labs Shakes Investor Suit Over 2022 Infant Formula Recall - Bloomberg Law News
FDA approves Freenome colorectal cancer blood test to be marketed by Abbott - Fierce Biotech
FDA approves Freenome's blood test for colorectal cancer screening - Reuters
Is Abbott Stock Attractive After Its Earnings and Guidance Update? - The Globe and Mail
FDA Approves Freenome’s SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S. - BioSpace
Abbott (ABT) Introduces FDA-Approved SimpleScreen CRC for Colore - GuruFocus
Abbott Laboratories (ABT) Fell as Guidance and Litigation Concerns Overshadowed Growth - Yahoo Finance
Zacks Investment Ideas feature highlights: General Motors, Abbott Laboratories and Johnson & Johnson - The Globe and Mail
Why Is Abbott Laboratories (NYSE:ABT) a Blue-Chip Stock to Watch? - Kalkine Media
Abbott stock trades steady as investors weigh recent earnings and medical device growth - Ad-hoc-news.de
Abbott Laboratories stock trades steadily as diagnostics and medical devices support earnings - Ad-hoc-news.de
PRIVACY ALERT: Abbott Laboratories and Exact Sciences Corporation Under Investigation for Data Breach of Patient Records - Los Angeles Downtown News
Abbott Laboratories (ABT) Could Be 14% Undervalued On Mixed Earnings And Growth Focus - simplywall.st
Abbott defeats shareholder lawsuit over 2022 infant formula recall | Business Information & News | FE - Westlaw Today
Health News Roundup: Abbott Wins Lawsuit, Measles Surge in the US, and More Updates - Devdiscourse
Abbott Beats 'Supersized' Investor Suit Over Formula Recall - Law360
Abbott Wins 7th Circ. Fight Over Baby Formula Warning - Law360
Patient Sues Abbott Labs, Exact Sciences in Data Theft - BankInfoSecurity
Abbott Notches Appellate Win in Bellwether Infant Formula Case - news.bloombergtax.com
Abbott defeats shareholder lawsuit over 2022 infant formula recall - Reuters
Q2 Earnings: Guidance Upgrades Push These 3 Stocks Higher - TradingView
FreeStyle Libre 3 Class Action Lawsuit Alleges Abbott Sold Defective Glucose Monitors - AboutLawsuits.com
Medtech Stocks Have Gotten Slammed. Why Abbott, Danaher, 4 More Are Bargains. - Barron's
Abbott Laboratories stock trades steady as diagnostics and medical devices support earnings momentum - AD HOC NEWS
Abbott Laboratories and Exact Sciences Corp Under Investigation for Data Breach of Patient Records - Schubert Jonckheer & Kolbe
Abbott Labs Accused Of Lax Security Over Shinyhunters Hack - Law360
Abbott Stock And 2 Dividend Ideas For Retirement Income - simplywall.st
ISRG vs. ABT: Which MedTech Giant Is the Smarter Investment Now? - TradingView
Abbott Faces Spine Stimulator Lawsuit Brought Jointly by 17 Injured Patients - AboutLawsuits.com
Abbott Laboratories (NYSE:ABT) Faces A Profit Test - Kalkine Media
Daiwa Securities Adjusts Price Target on Abbott Laboratories to $103 From $92, Maintains Neutral Rating - marketscreener.com
Same Industry, Less Money: What Boston Scientific and ResMed Offer That Abbott Laboratories Does Not - Trefis
Abbott Laboratories (ABT) Is Up 12.7% After Revenue Rises But Earnings Shrink In Q2 2026 - simplywall.st
Abbott Laboratories (ABT) Earnings Drew Fresh Attention, Is It Still Below Fair Value? - Yahoo Finance
Abbott Laboratories stock holds gains after strong diagnostics and medical devices momentum - Ad-hoc-news.de
Abbott Laboratories (ABT) Stock Forecasts - Yahoo Finance
Abbott (NYSE:ABT) Faces A Crucial Valuation Test - Kalkine Media
Leerink Partners Adjusts Price Target on Abbott Laboratories to $109 From $106, Maintains Market Perform Rating - marketscreener.com
Cancer Diagnostics Breached At Abbott As 2026 Medtech Cyberattack Run Continues - insights.citeline.com
Abbott (ABT) Stock May Be 32% Undervalued As Legal Overhang Fades - simplywall.st
Abbott Laboratories stock steadies as medical devices and diagnostics underpin growth - Ad-hoc-news.de
Abbott Laboratories stock underperforms Tuesday when compared to competitors - MarketWatch
Patients sue diagnostics company over data breach - Courthouse News
Johnson & Johnson vs Abbott Laboratories: Two Healthcare Giants on Opposite Trajectories - Yahoo Finance
Abbott Is A Leader Who Cares About Hoosiers And Animals - InkFreeNews.com
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Abbott Confirms Unauthorized Access to Cancer Diagnostics Systems - cyberpress.org
NewsAbbott Investigates Cybersecurity Incidents After Hackers Claim Data Breach - teiss
Lobbying Update: $1,150,000 of ABBOTT LABORATORIES lobbying was just disclosed - Quiver Quantitative
Abbott Laboratories stock trades steadily as diagnostics and medical devices underpin earnings momen - Ad-hoc-news.de
Craneware, Abbott Probe Separate Health Data Theft Incidents - BankInfoSecurity
Abbott Laboratories (NYSE:ABT) Faces A Major Medical Device Growth Test - Kalkine Media
Healthcare giant Abbott probes two cyber incidents amid extortion claims - Security Boulevard
ShinyHunters hit medial giant Abbott, disrupting cancer drug research and more - Yahoo Tech
Abbott Laboratories (ABT) Gets a Buy from Raymond James - The Globe and Mail
Abbott Investigating Cyberattack Claims From Two Threat Actors - The HIPAA Journal
1.84%
0.30%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):